glp-1 drugs in development Receptor Agonist Market Size & Analysis, 2026-2033 History of glucagon-like peptide-1 receptor
Description
Popik, P., Kos, T., Zhang, Y
Front Endocrinol 2018
Many neuroprotective effects remain to be causally associated with anti-inflammatory mechanisms, and some Alzheimers disease mouse models did not respond to semaglutide or tirzepatide, emphasizing that not all neural benefits are consistent across studies
Larsen PJ, Holst JJ
Conclusion: This meta-analysis demonstrates that GLP-1 receptor agonists are a promising therapeutic option for patients with IIH, demonstrating significant efficacy in reducing intracranial pressure-related symptoms such as BMI, headache frequency, papilledema, and visual disturbances
